TY - JOUR
T1 - The added value of a new high-performance ring-gantry CBCT imaging system for prostate cancer patients
AU - Kunnen, Britt
AU - J.A.J. van de Schoot, Agustinus
AU - Fremeijer, Kimm P.
AU - Nicolai-Koornneef, Elise M.
AU - Offereins-van Harten, Kirsten
AU - Sluijter, Judith H.
AU - Sijtsema, Nienke D.
AU - Oomen-de Hoop, Esther
AU - el Yaakoubi, Abdelmounaim
AU - Froklage, Femke E.
AU - de Vries, Kim C.
AU - Dirkx, Maarten L.P.
AU - Penninkhof, Joan J.
AU - Petit, Steven F.
N1 - Publisher Copyright: © 2024
PY - 2024/11
Y1 - 2024/11
N2 - Background and purpose: A novel Cone-Beam Computed Tomography (CBCT) named HyperSight provides superior CBCT image quality compared to conventional ring gantry CBCT imaging, and it is suitable for dose calculations for prostate cancer, but it comes with considerable additional costs. The aim of this study was to determine the added value of HyperSight CBCT imaging compared to conventional CBCT imaging in terms of organ visibility in the male pelvic region. Materials and methods: Twenty prostate cancer patients were included in this prospective clinical study. For each patient three CBCT pairs, consisting of HyperSight and conventional CBCT scans acquired on consecutive days, were included. CBCT scans were evaluated by four observers in terms of visibility of the prostate, bladder, rectum and seminal vesicles. Visibility was scored on a 1-to-5 scale and by annotating axial slices where the organs were hard to delineate. Lastly, observers indicated whether the CBCT scans were of sufficient quality for an online adaptive radiation therapy workflow. Results: All four organs were better visible on HyperSight CBCT scans compared to conventional CBCT scans. The mean visibility scores increased from 3.1 to 4.5 on a 1––5 scale of and the mean number of annotated slices reduced from 4.5 to 1.1. 99% Of the HyperSight CBCT scans were considered suitable for an online adaptive workflow vs 25–83% for the conventional CBCT scans. Conclusion: HyperSight CBCT scans yielded a visibility of prostate, bladder, rectum and seminal vesicles comparable to planning CT scans and, can replace a repeat planning CT scan in case of anatomical changes requiring a new treatment plan.
AB - Background and purpose: A novel Cone-Beam Computed Tomography (CBCT) named HyperSight provides superior CBCT image quality compared to conventional ring gantry CBCT imaging, and it is suitable for dose calculations for prostate cancer, but it comes with considerable additional costs. The aim of this study was to determine the added value of HyperSight CBCT imaging compared to conventional CBCT imaging in terms of organ visibility in the male pelvic region. Materials and methods: Twenty prostate cancer patients were included in this prospective clinical study. For each patient three CBCT pairs, consisting of HyperSight and conventional CBCT scans acquired on consecutive days, were included. CBCT scans were evaluated by four observers in terms of visibility of the prostate, bladder, rectum and seminal vesicles. Visibility was scored on a 1-to-5 scale and by annotating axial slices where the organs were hard to delineate. Lastly, observers indicated whether the CBCT scans were of sufficient quality for an online adaptive radiation therapy workflow. Results: All four organs were better visible on HyperSight CBCT scans compared to conventional CBCT scans. The mean visibility scores increased from 3.1 to 4.5 on a 1––5 scale of and the mean number of annotated slices reduced from 4.5 to 1.1. 99% Of the HyperSight CBCT scans were considered suitable for an online adaptive workflow vs 25–83% for the conventional CBCT scans. Conclusion: HyperSight CBCT scans yielded a visibility of prostate, bladder, rectum and seminal vesicles comparable to planning CT scans and, can replace a repeat planning CT scan in case of anatomical changes requiring a new treatment plan.
UR - http://www.scopus.com/inward/record.url?scp=85201607563&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2024.110458
DO - 10.1016/j.radonc.2024.110458
M3 - Article
C2 - 39069089
AN - SCOPUS:85201607563
SN - 0167-8140
VL - 200
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
M1 - 110458
ER -